Healthcare / Medical Instruments & SuppliesStockholm
$17.00
+0.85 (+5.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $9.0M · quality 35.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$189M
P/E
21.0x
↑EV/EBITDA
11.0x
↓ROE
10.4%
↑Gross Margin
75.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.6%
FCF CAGR
—
FCF margin
7.0%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $64.8M · net income $9.8M · FCF $4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $64.8M | $64.8M | $62.4M | $50.1M | $33.6M |
| Net Income | $9.8M | $9.8M | $13.5M | $11.9M | $3.8M |
| EBITDA | $14.1M | $14.1M | $18.7M | $16.6M | $7.1M |
| EPS | — | — | 1.29 | 1.14 | 0.37 |
| Gross Margin | 75.4% | 75.4% | 74.8% | 75.6% | 71.7% |
| Operating Margin | 13.3% | 13.3% | 22.2% | 29.8% | 13.3% |
| Net Margin | 15.1% | 15.1% | 21.6% | 23.7% | 11.4% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.05 |
| Current Ratio | 10.27 | 10.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.5M | $4.5M | $11.3M | $9.0M | $-2.1M |
| Returns | |||||
| ROE | 10.4% | 10.4% | 21.5% | 24.7% | 10.6% |
| Valuation | |||||
| P/E | 20.99 | 20.99 | 30.07 | 32.03 | 22.54 |
| EV/EBITDA | 10.96 | 10.96 | 20.73 | 22.21 | 11.89 |
| P/B | 2.00 | 2.00 | 6.46 | 7.90 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 3.9% | 3.9% | 24.5% | 49.4% | — |
| EPS Growth | — | — | 13.2% | 210.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.29 → n/d
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.